Company Overview: Thermo Fisher specializes in manufacturing scientific instruments, consumables, and chemicals for various sectors including pharmaceuticals, healthcare, and research institutions.
Product Offerings: The company provides a wide range of products such as analytical instruments, lab equipment, software, reagents, and supplies tailored for hospitals, clinical labs, universities, and government agencies.
TMO
$562.56+Infinity%1D
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 615.44 USD with a low forecast of 561.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 615.44 USD with a low forecast of 561.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 570.160
Low
561.00
Averages
615.44
High
675.00
Current: 570.160
Low
561.00
Averages
615.44
High
675.00
BofA
Buy
maintain
$650 -> $700
2025-12-15
New
Reason
BofA
Price Target
$650 -> $700
2025-12-15
New
maintain
Buy
Reason
BofA raised the firm's price target on Thermo Fisher to $700 from $650 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
Wells Fargo
NULL -> Overweight
maintain
$635 -> $675
2025-12-15
New
Reason
Wells Fargo
Price Target
$635 -> $675
2025-12-15
New
maintain
NULL -> Overweight
Reason
Wells Fargo raised the firm's price target on Thermo Fisher to $675 from $635 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Citi
Patrick Donnelly
Neutral -> Buy
upgrade
$580 -> $660
2025-12-11
Reason
Citi
Patrick Donnelly
Price Target
$580 -> $660
2025-12-11
upgrade
Neutral -> Buy
Reason
Citi analyst Patrick Donnelly upgraded Thermo Fisher to Buy from Neutral with a price target of $660, up from $580. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. Citi sees Thermo Fisher benefitting from increased pharma spending and onshoring tailwinds.
Goldman Sachs
Evie Koslosky
initiated
$685
2025-12-09
Reason
Goldman Sachs
Evie Koslosky
Price Target
$685
2025-12-09
initiated
Reason
Goldman Sachs analyst Evie Koslosky initiated coverage of Thermo Fisher with a Buy rating and $685 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
